Quetiapine Pharmacokinetics and Clinical Efficacy

Pharmacokinetic Profile

• Quetiapine has a half-life of approximately 6-7 hours, which is considerably shorter than many other atypical antipsychotics, necessitating different dosing considerations 1
• The immediate-release formulation requires twice-daily dosing due to the 6-7 hour half-life, while the extended-release formulation allows once-daily administration 1

Special Population Considerations

• Quetiapine should be avoided in elderly patients with dementia-related psychosis due to increased mortality risk, as warned by FDA guidelines 2
• In open-label studies of youth with treatment-resistant childhood-onset schizophrenia, quetiapine was noted to be safe and effective, though systematic studies are limited 3

Common Pitfalls and Clinical Considerations

• Never crush extended-release formulations, as this destroys the controlled-release mechanism and can lead to dose dumping, increased side effects, and loss of therapeutic efficacy 2
• When switching from other antipsychotics to quetiapine, the short half-life (6-7 hours) requires different tapering strategies compared to long-acting agents like aripiprazole (75-hour half-life) 1